Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.50 |
| ▸ | AR | P10275 | 4/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30720887 | 1.00 | CRBN (0.50) | CRBNARBTKITKHPGDS | |
| SCHEMBL31043971 | 0.94 | CRBN (0.56) | CRBNARBTKITKHPGDS | |
| SCHEMBL29927797 | 0.89 | CRBN (0.55) | CRBNARBTKITKHPGDS | |
| SCHEMBL29132249 | 0.89 | CRBN (0.55) | CRBNARBTKITKHPGDS | |
| SCHEMBL29927690 | 0.88 | CRBN (0.49) | CRBNARBTKITKHPGDS | |
| SCHEMBL29132173 | 0.88 | CRBN (0.49) | CRBNARBTKITKHPGDS | |
| SCHEMBL29927467 | 0.88 | CRBN (0.49) | CRBNARBTKITKHPGDS | |
| SCHEMBL29132214 | 0.88 | CRBN (0.49) | CRBNARBTKITKHPGDS | |
| SCHEMBL23860158 | 0.87 | CRBN (0.49) | CRBNARBTKITKHPGDS | |
| SCHEMBL31619119 | 0.87 | CRBN (0.49) | CRBNARBTKITKHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CRBN 2/4885AR 3324/4885BTK 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.